A federal court ruled a stent system made by Boston Scientific Corp. (BSX) doesn't infringe on Johnson & Johnson (JNJ) patents, a judgment that helps the medical-device maker notch a win in a patent war with the health-care products giant.
Johnson & Johnson had alleged in a 2008 suit that Boston Scientific's Promus everolimus-eluting coronary stent system infringed on two of its patents.
Boston Scientific on Monday touted a decision from a federal court in New Jersey, saying the court had found the patents to be invalid.
"Boston Scientific will continue to vigorously defend against any claims of infringement," said Tim Pratt, general counsel for the company.
A spokeswoman for Johnson & Johnson couldn't immediately be reached for comment.
The two companies have been locked in a long-running battle over intellectual property for heart stents, with both scoring some victories along the way.
Johnson & Johnson shares were recently down slightly to $65.25 premarket, while Boston Scientific were up 1.2% to $6.05.
-By Mia Lamar, Dow Jones Newswires; 212-416-3207; firstname.lastname@example.org